Statement: The majority of patients in the primary trial and the secondary trial experienced an adverse event.
Primary_evidence: Adverse Events 1:   Total: 24/32 (75.00%)   Disseminated intravascular coagulation * 1/32 (3.13%)   Febrile neutropenia * 1/32 (3.13%)   Adrenal insufficiency * 1/32 (3.13%)   Endocrine disorder * 1/32 (3.13%)   Chills * 1/32 (3.13%)   Fatigue * 1/32 (3.13%)   Fever * 1/32 (3.13%)   Multi-organ failure * 1/32 (3.13%)   Hepatic failure * 1/32 (3.13%)   Infection * 1/32 (3.13%)   Sepsis * 1/32 (3.13%)
Secondary_evidence: Adverse Events 1:   Total: 30/112 (26.79%)   Thrombocytopenia 1/112 (0.89%)   Dysphagia 1/112 (0.89%)   Haemorrhoidal haemorrhage 1/112 (0.89%)   Oesophageal stenosis 1/112 (0.89%)   Upper gastrointestinal haemorrhage 1/112 (0.89%)   Asthenia 1/112 (0.89%)   Disease progression 1/112 (0.89%)   Hepatotoxicity 1/112 (0.89%)   Cellulitis 3/112 (2.68%)   Pneumonia 2/112 (1.79%)   Osteomyelitis 1/112 (0.89%)